Bergman, P.J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., Wulderk, M., Jeffers, Y., Sadelain, M., Hohenhaus, A.E., Segal, N., Gregor, P., Engelhorn, M., Riviere, I., Houghton, A.N. and Wolchok, J.D. (2003) Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase: A Phase I Trial. Clinical Cancer Research, 9, 1284-1290.

has been cited by the following article:

• TITLE: DNA Vaccines Approach: From Concepts to Applications

  AUTHORS: Vanessa Bastos Pereira, Meritxell Zurita-Turk, Tessália Diniz Luerce Saraiva, Camila Prósperi De Castro, Bianca Mendes Souza, Pamela Mancha Agresti, Fernanda Alvarenga Lima, Vanessa Nathalie Pfeiffer, Marcela Santiago Pacheco Azevedo, Clarissa Santos Rocha, Daniela Santos Pontes, Vasco Azevedo, Anderson Miyoshi

  KEYWORDS: DNA Vaccines, Vector Design, Delivery Systems, Approved DNA Vaccines, Bacterial Delivery

  JOURNAL NAME: World Journal of Vaccines, Vol.4 No.2, April 18, 2014

  ABSTRACT: DNA vaccines are the third generation vaccines based on purified plasmid preparations containing transgenes that encode antigenic/therapeutic proteins or peptides capable of triggering an immune response against a wide range of diseases. This vaccine platform presents several attributes that confer distinct advantages over other vaccine technologies in terms of safety, ease of fabrication and stability. Many aspects, such as antigen expression and especially vector design, are under study because of their great influence on immunogenicity and efficacy of DNA vaccines. In this regard, with the attempt of improving the efficiency of DNA vaccines, co-expression of stimulatory sequences and diverse vector delivery systems are being optimized. With this in mind, this review aims to giving a conceptual approach of DNA vaccines, explaining their mechanisms of action and listing the already licensed veterinary DNA vaccines presented in the market.